France: The fight against biopiracy and the Nagoya Protocol
Managing IP is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

France: The fight against biopiracy and the Nagoya Protocol

In 1992, the Rio Convention on Biodiversity set the goal of fighting practices known as biopiracy and which are generally seen in developing countries. These involve identifying certain genetic resources of a country and indigenous traditional knowledge that may be linked to their use, developing them, protecting them through patents and extracting commercial gain without any benefit to the indigenous populations in question. The Nagoya Protocol, an extension of the Rio Convention, enshrines a move from mere declarations of intent to concrete measures.

The Nagoya Protocol has been ratified by more than 100 countries, including France and its main goal is to ensure that each member country incorporates into its national law provisions seeking to:

  • make access to genetic resources in its territory, and such traditional knowledge as may be linked thereto, the subject of a system of prior registration or authorisation;

  • ensure that the advantages arising from the use of the said resources and knowledge are indeed shared with indigenous populations.

As far as the European Union is concerned, the principles of the Nagoya Protocol have been incorporated into Regulation 511/2014 and Implementing Regulation 2015/1866. In France, the provisions of the Protocol and the above-mentioned EU Regulations have for the most part been incorporated into the Environmental Code. The latter notably ensures, for all research activity (involving genetic and/or biochemical compositions) concerning genetic resources available in French territory, mandatory compliance with the following formal requirements:

  • filing a declaration prior to accessing any genetic resources with a view to their study, the keeping thereof in a collection or uses thereof not being linked to immediate commercial development;

  • obtaining an authorisation and entering into a contract concerning the sharing of benefits prior to any access to genetic resources with a view to their study and commercial uses thereof, as well as prior to any use of traditional knowledge linked to genetic resources (a specific authorisation and procedure have been laid down to this end).

Furthermore, in cases where there is simultaneous use both of genetic resources and traditional knowledge linked thereto, supplementary reporting obligations are foreseen in the two following cases:

  • for obtaining funding in order to carry out research;

  • for the final development of a product which, if it gives rise to the filing of a patent application, will also result in the requirement to forward to the French Intellectual Property Office (INPI) supplementary information using the form appearing in Annex III of the Implementing Regulation 2015/1866.

It may be noted that the corresponding provisions of the Environmental Code are accompanied by criminal penalties.

Francis Declercq


Cabinet Beau de Loménie158, rue de l’UniversitéF - 75340 Paris Cedex 07 FranceTel: +33 1 44 18 89 00Fax: +33 1 44 18 04 23contact@bdl-ip.comwww.bdl-ip.com

more from across site and ros bottom lb

More from across our site

Each week Managing IP speaks to a different IP lawyer about their life and career
Ireland joining the UPC would offer plenty of opportunities to local attorneys but there are fears that upcoming referendum could get ‘lost in the noise’
Attorneys at four firms reveal the business opportunities that stem from patent licensing agreements in the life sciences sector
We provide a rundown of Managing IP’s news and analysis from the week, and review what’s been happening elsewhere in IP
Counsel at four firms explain their lateral hiring policies and how they retain existing lawyers
Lori Gordon, who has joined from Perkins Coie, says she hopes to turn Goodwin into a 'premier' destination for PTAB work
The LMG Life Sciences Awards is thrilled to present the shortlist for the 2024 EMEA Awards.
Partners at LeanWill Law Firm, a newly launched domestic firm in China, discuss IP opportunities and which clients they plan to target
Each week Managing IP speaks to a different IP lawyer about their life and career
A survey of more than 25,000 in-house lawyers reveals that embracing technology could help law firms win new business
Gift this article